Safety profile of the oral iron chelator deferiprone: a multicentre study.

@article{Cohen2000SafetyPO,
  title={Safety profile of the oral iron chelator deferiprone: a multicentre study.},
  author={Alan R Cohen and Renzo Galanello and Antonio Morales Piga and Antonella Dipalma and Calogero Vullo and Fernando Tricta},
  journal={British journal of haematology},
  year={2000},
  volume={108 2},
  pages={305-12}
}
In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder forms of neutropenia and other side-effects. To determine the incidence of these events, we performed a multicentre prospective study of the chelator. Blood counts were performed weekly, and confirmed neutropenia mandated discontinuation of therapy. Among 187 patients with thalassaemia major, the incidence of agranulocytosis (neutrophils < 0.5 x 109/l) was 0.6/100… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

Similar Papers

Loading similar papers…